Lipocine initiates BLOOM Phase 3 study for postpartum depression.
Lipocine began its BLOOM Phase 3 trial for LPCN 1154 to support a potential 505(b)(2) NDA, utilizing existing resources despite past data anomalies.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day